Skip to main content
Figure 3 | Critical Care

Figure 3

From: Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

Figure 3

Twenty-eight-day mortality in all randomly assigned patients with an APACHE II score of greater than or equal to 25 in ADDRESS (a) and PROWESS (b) with no patients removed from the analysis and also with the first through fourth patients enrolled at each site removed. Note: 0 represents the results for the entire population, and 1 through 4 correspond to the analysis with the first through fourth patients from each site removed. ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, drotrecogin alfa (activated); PBO, placebo; PROWESS, Protein C Worldwide Evaluation in Severe Sepsis.

Back to article page

Critical Care

ISSN: 1364-8535